IL232267A - Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective - Google Patents

Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective

Info

Publication number
IL232267A
IL232267A IL232267A IL23226714A IL232267A IL 232267 A IL232267 A IL 232267A IL 232267 A IL232267 A IL 232267A IL 23226714 A IL23226714 A IL 23226714A IL 232267 A IL232267 A IL 232267A
Authority
IL
Israel
Prior art keywords
phenylimidazol
inhibition
diseases
indicated
treatment
Prior art date
Application number
IL232267A
Other languages
English (en)
Hebrew (he)
Other versions
IL232267A0 (en
Inventor
Kaur Bagal Sharanjeet
Ian Kemp Mark
Charles Miller Duncan
Murata Yoshihisa
Original Assignee
Pfizer Ltd
Kaur Bagal Sharanjeet
Ian Kemp Mark
Charles Miller Duncan
Murata Yoshihisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL232267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd, Kaur Bagal Sharanjeet, Ian Kemp Mark, Charles Miller Duncan, Murata Yoshihisa filed Critical Pfizer Ltd
Publication of IL232267A0 publication Critical patent/IL232267A0/en
Publication of IL232267A publication Critical patent/IL232267A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL232267A 2011-10-26 2014-04-27 Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective IL232267A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (2)

Publication Number Publication Date
IL232267A0 IL232267A0 (en) 2014-06-30
IL232267A true IL232267A (en) 2016-10-31

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232267A IL232267A (en) 2011-10-26 2014-04-27 Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective

Country Status (28)

Country Link
US (1) US9079878B2 (enExample)
EP (1) EP2771335A2 (enExample)
JP (1) JP5946538B2 (enExample)
KR (1) KR101586966B1 (enExample)
CN (1) CN103906746B (enExample)
AP (1) AP2014007579A0 (enExample)
AU (1) AU2012328034B2 (enExample)
BR (1) BR112014009102A2 (enExample)
CA (1) CA2850925C (enExample)
CL (1) CL2014000956A1 (enExample)
CO (1) CO6940427A2 (enExample)
CR (1) CR20140185A (enExample)
CU (1) CU20140046A7 (enExample)
DO (1) DOP2014000085A (enExample)
EA (1) EA023375B1 (enExample)
EC (1) ECSP14013324A (enExample)
GT (1) GT201400079A (enExample)
IL (1) IL232267A (enExample)
MD (1) MD20140037A2 (enExample)
MX (1) MX337469B (enExample)
NI (1) NI201400031A (enExample)
PE (1) PE20141682A1 (enExample)
PH (1) PH12014500919A1 (enExample)
SG (1) SG11201401032YA (enExample)
TN (1) TN2014000147A1 (enExample)
UA (1) UA109220C2 (enExample)
WO (1) WO2013061205A2 (enExample)
ZA (1) ZA201402281B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1199262A1 (en) * 2011-09-14 2015-06-26 Dow Agrosciences Llc Methods and systems for forming boronic acids and intermediates thereof
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
CN107206015A (zh) * 2014-10-24 2017-09-26 阿维塔斯有限公司 透细胞质膜的传递
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
CN116676292A (zh) 2015-12-30 2023-09-01 阿维塔斯有限公司 基因编辑蛋白和组合物向细胞和组织的无载体递送
AU2017292173B2 (en) 2016-07-06 2022-01-13 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
CN110214149B (zh) 2016-07-06 2024-05-14 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
MA54076A (fr) 2018-11-02 2022-02-09 Merck Sharp & Dohme 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
PE20251179A1 (es) 2022-04-22 2025-04-23 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
TW202408501A (zh) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
EP4511117A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
SI1747210T1 (sl) * 2004-05-07 2010-09-30 Warner Lambert Co ali monosubstituirani fenolin in tiofenolni derivati uporabni kot ligandi H
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
CA2584785A1 (en) 2004-10-27 2006-05-04 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of nav1.8
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
US20100227872A1 (en) 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
CN103906746A (zh) 2014-07-02
PE20141682A1 (es) 2014-11-14
EP2771335A2 (en) 2014-09-03
CA2850925C (en) 2017-01-10
CO6940427A2 (es) 2014-05-09
GT201400079A (es) 2015-06-02
AU2012328034B2 (en) 2015-04-23
US9079878B2 (en) 2015-07-14
KR101586966B1 (ko) 2016-01-19
UA109220C2 (uk) 2015-07-27
CN103906746B (zh) 2015-12-09
US20140296313A1 (en) 2014-10-02
MD20140037A2 (ro) 2014-08-31
PH12014500919A1 (en) 2014-06-09
CR20140185A (es) 2014-06-03
HK1198650A1 (en) 2015-05-22
AU2012328034A1 (en) 2014-05-15
ZA201402281B (en) 2015-11-25
DOP2014000085A (es) 2014-08-31
NI201400031A (es) 2014-10-01
CU20140046A7 (es) 2014-10-02
JP5946538B2 (ja) 2016-07-06
BR112014009102A2 (pt) 2017-04-18
IL232267A0 (en) 2014-06-30
SG11201401032YA (en) 2014-07-30
ECSP14013324A (es) 2014-05-31
WO2013061205A3 (en) 2013-06-27
AP2014007579A0 (en) 2014-04-30
MX337469B (es) 2016-03-02
EA201490864A1 (ru) 2014-08-29
KR20140069234A (ko) 2014-06-09
TN2014000147A1 (fr) 2015-09-30
EA023375B1 (ru) 2016-05-31
WO2013061205A2 (en) 2013-05-02
NZ623090A (en) 2015-10-30
CL2014000956A1 (es) 2014-07-18
CA2850925A1 (en) 2013-05-02
JP2014530900A (ja) 2014-11-20
MX2014004738A (es) 2014-08-01
WO2013061205A8 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
PH12017501306A1 (en) Inhibitors of histone demethylases
GB201118656D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
MY190408A (en) Compositions and methods for treating cns disorders
PH12015501609A1 (en) Phenicol antibacterials
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2015010829A (es) Compuestos terapeuticos y sus usos.
EP3069720A4 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
HK1217092A1 (zh) 治疗性化合物及其用途
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
IN2014MN02056A (enExample)
IN2014DN06869A (enExample)
WO2013040227A3 (en) Therapeutic compounds
PH12016502352A1 (en) Pharmaceutical composition
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
UA110131C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ
IN2015DN02109A (enExample)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees